Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -5.85%5.57B | -0.37%23.86B | -4.98%5.96B | -0.78%5.91B | 2.44%6.08B | 2.16%5.92B | 3.16%23.95B | 1.98%6.27B | 1.98%5.95B | -0.06%5.94B |
Cost of revenue | -5.87%3.58B | 12.83%16.57B | 3.80%4.09B | 0.07%3.64B | 40.60%5.03B | 7.95%3.81B | 11.27%14.69B | 13.68%3.94B | 10.60%3.64B | 4.08%3.58B |
Gross profit | -5.82%1.99B | -21.30%7.29B | -19.85%1.87B | -2.12%2.26B | -55.38%1.05B | -6.85%2.11B | -7.53%9.27B | -13.17%2.33B | -9.17%2.31B | -5.75%2.36B |
Operating expense | 8.92%1.61B | -11.50%6.27B | -19.95%1.47B | -0.99%1.73B | -8.05%1.58B | -16.45%1.48B | -0.30%7.08B | 4.72%1.84B | -1.87%1.75B | 8.25%1.72B |
Staff costs | 2.80%855.98M | 1.40%3.25B | -14.17%740.57M | 10.21%862.43M | 4.27%809.42M | 6.94%832.63M | 3.75%3.2B | 3.19%862.86M | 5.10%782.53M | 6.63%776.25M |
Research and development costs | 15.93%39.72M | -81.26%216.98M | -75.76%53.82M | -70.12%72.02M | -81.63%56.87M | -91.10%34.26M | -33.58%1.16B | -46.84%222.03M | -47.00%241.05M | -8.12%309.6M |
Depreciation and amortization | 16.02%36.56M | -35.92%127.79M | -30.33%35.57M | -39.86%29.6M | -37.48%31.11M | -36.19%31.51M | -1.02%199.43M | 2.84%51.06M | 0.04%49.22M | -2.73%49.76M |
-Depreciation | 16.66%36.43M | 12.72%126.65M | 20.46%35.29M | 6.79%29.31M | 10.12%30.82M | 13.06%31.23M | -1.80%112.35M | 5.06%29.29M | 0.08%27.45M | -4.74%27.99M |
-Amortization | -54.20%131K | -98.68%1.15M | -98.68%287K | -98.69%286K | -98.68%287K | -98.69%286K | 0.00%87.08M | 0.00%21.77M | 0.00%21.77M | 0.00%21.77M |
Other operating expenses | 16.87%680.91M | 6.08%2.68B | -8.65%642.29M | 13.56%766.29M | 16.94%687.24M | 4.15%582.6M | 21.69%2.53B | 55.35%703.14M | 26.78%674.78M | 23.48%587.68M |
Operating profit | -40.52%374.38M | -53.09%1.02B | -19.50%393.02M | -5.62%533.12M | -183.30%-531.12M | 27.68%629.42M | -25.12%2.18B | -47.17%488.22M | -26.17%564.86M | -30.15%637.62M |
Net non-operating interest income (expenses) | 20.10%10.75M | 53.69%35.35M | 47.01%11.15M | 63.04%13.16M | -60.85%2.09M | 345.94%8.95M | 457.17%23M | 571.15%7.58M | 1,013.24%8.07M | 396.56%5.34M |
Non-operating interest income | 20.16%10.92M | 52.04%35.84M | 45.62%11.26M | 61.32%13.28M | -59.72%2.22M | 331.53%9.09M | 405.06%23.58M | 536.46%7.73M | 876.28%8.23M | 348.82%5.51M |
Non-operating interest expense | 23.91%171K | -13.89%496K | -24.83%112K | -25.79%118K | -24.26%128K | 39.39%138K | 6.67%576K | 75.29%149K | 34.75%159K | 11.18%169K |
Net investment income | -40.73%5.18M | 374.18%7.01M | -115.00%-1.32M | 29.58%-2.3M | 125.61%1.88M | 1,259.81%8.75M | 28.46%-2.56M | 142.60%8.8M | -280.63%-3.26M | -109.11%-7.34M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 139K | -101.82%-203K | -41.67%1.16M | 0 | -6.38%11.18M | -40.01%1.99M | 0 | |||
Income from associates and other participating interests | -51.88%397K | 65.73%2.72M | 101.97%717K | 222.28%651K | -3.14%525K | 52.50%825K | -19.77%1.64M | 113.86%355K | -18.88%202K | -18.37%542K |
Special income (charges) | 99.94%-52K | 72.59%-89.67M | 82.90%-868K | 99.97%-4K | 99.76%-737K | -6,446.99%-88.06M | -1,889.61%-327.15M | 54.16%-5.08M | -273.65%-15.13M | -305.6M |
Less:Restructuring and mergern&acquisition | ---- | --0 | --0 | ---- | ---- | ---- | --305.09M | --0 | --0 | ---- |
Less:Other special charges | -92.34%52K | -89.63%2.29M | -82.90%868K | -99.97%4K | 45.36%737K | -49.52%679K | 34.17%22.06M | -54.16%5.08M | 273.65%15.13M | --507K |
Less:Write off | --0 | --87.38M | --0 | --0 | --0 | --87.38M | --0 | --0 | --0 | --0 |
Other non-operating income (expenses) | -29.12%460K | -46.77%3.44M | -45.48%1.01M | -56.47%1.14M | -3.78%637K | -50.83%649K | -3.15%6.46M | 64.03%1.85M | -28.83%2.63M | -15.45%662K |
Income before tax | -30.20%391.26M | -48.16%983.08M | -19.62%404.87M | -2.08%545.78M | -255.13%-528.09M | 13.30%560.53M | -35.08%1.9B | -45.40%503.72M | -27.12%557.37M | -62.97%340.41M |
Income tax | -26.07%142.88M | -16.59%379.9M | -10.87%132.92M | 58.95%200.23M | -262.38%-146.52M | 114.44%193.27M | -47.61%455.46M | -62.69%149.13M | -35.15%125.97M | -53.35%90.23M |
Net income | -32.37%248.38M | -58.13%603.18M | -23.31%271.95M | -19.90%345.55M | -252.52%-381.57M | -9.23%367.26M | -29.77%1.44B | -32.17%354.59M | -24.39%431.39M | -65.53%250.18M |
Net income continuous operations | -32.37%248.38M | -58.13%603.18M | -23.31%271.95M | -19.90%345.55M | -252.52%-381.57M | -9.23%367.26M | -29.77%1.44B | -32.17%354.59M | -24.39%431.39M | -65.53%250.18M |
Noncontrolling interests | 0 | 0 | ||||||||
Net income attributable to the company | -32.37%248.38M | -58.13%603.18M | -23.31%271.95M | -19.90%345.55M | -252.52%-381.57M | -9.23%367.26M | -29.77%1.44B | -32.17%354.59M | -24.39%431.39M | -65.53%250.18M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -32.37%248.38M | -58.13%603.18M | -23.31%271.95M | -19.90%345.55M | -252.52%-381.57M | -9.23%367.26M | -29.77%1.44B | -32.17%354.59M | -24.39%431.39M | -65.53%250.18M |
Gross dividend payment | ||||||||||
Basic earnings per share | -32.38%15.33 | -58.14%37.23 | -23.34%16.78 | -19.90%21.33 | -252.53%-23.55 | -9.25%22.67 | -29.77%88.94 | -32.19%21.89 | -24.39%26.63 | -65.54%15.44 |
Diluted earnings per share | -32.38%15.33 | -58.14%37.23 | -23.34%16.78 | -19.90%21.33 | -252.55%-23.5544 | -9.25%22.67 | -29.77%88.94 | -32.17%21.8882 | -24.39%26.6293 | -65.54%15.44 |
Dividend per share | 0 | 0.00%90 | 0.00%45 | 0 | 0.00%45 | 0 | 0.00%90 | 0.00%45 | 0 | 0.00%45 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |